Health Outcomes
Resource Center
Featured
08/26/2026
Anthony Calabro, MA
The FDA approved the first-in-class targeted therapy based on a clinical trial evaluating overall survival among adults with previously treated metastatic pancreatic adenocarcinoma.
08/26/2026
08/25/2026
Anthony Calabro, MA
Five-year survival after Hodgkin lymphoma does not eliminate excess mortality risk. What does the long-term pattern of deaths reveal about survivorship after the disease?
08/25/2026
08/20/2026
Anthony Calabro, MA
Intismeran autogene plus pembrolizumab met the primary recurrence-free survival and a key secondary distant metastasis-free survival endpoint in the phase 3 INTerpath-001 trial in patients with completely...
08/20/2026
Interactive Features
08/25/2026
Anthony Calabro, MA
Five-year survival after Hodgkin lymphoma does not eliminate excess mortality risk. What does the long-term pattern of deaths reveal about survivorship after the disease?
08/25/2026
08/03/2026
Anthony Calabro, MA
This quiz reviews how clinicians should interpret lower-intensity pregnancy activity patterns beyond moderate- to vigorous-intensity exercise.
08/03/2026
06/21/2026
Anthony Calabro, MA
Explore our latest collection of must-read articles for primary care physicians—all in one place. This expertly curated page brings together timely, practical insights on combatting physician burnout to...
06/21/2026
06/15/2026
Anthony Calabro, MA
Sleep quality depends on more than duration alone. Test your understanding of a key marker of sleep continuity.
06/15/2026
11/13/2025
Anthony Calabro, MA
How do patients with chronic urticaria weigh efficacy, safety, and convenience when selecting therapy? This quiz, based on a JAMA Dermatology systematic review, explores patient values and preferences to...
11/13/2025
Clinical Insights
06/04/2026
Norman Weinberg, MD
In this podcast, Norman Weinberg, MD, a retired primary care internist with over 40 years of experience, discusses the intricacies of managing physician behavior and diagnostic errors.
06/04/2026
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
11/12/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
In this episode of Ask the Experts, dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares what's unique about the formulations of ZORYVE® (roflumilast). Mr. DiRuggiero discusses how...
11/12/2025
11/04/2025
Daniel Lenihan, MD, FACC, FESC
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
11/04/2025
SOHO 2025 Conference Coverage
SOHO 2025 Conference Coverage
09/23/2025
Junaid Anwar, MD
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
09/23/2025
